The Newsroom of Omnicyte

Peter Leonardi
OmniCyte
+1 917-439-7479

Omnicyte
23 Business Park Drive
Branford, Connecticut, 06405
United States
+1 917-439-7479

OmniCyte is a preclinical stage, immunology based, biotechnology company located in Branford Connecticut. The company was founded with a mission to develop targeted treatments to address unmet needs in cancer. Our therapeutics are developed on our proprietary, Targeted Immune Activation, platform technology. The platform consists of a bi-specific protein complex, with a conserved domain that activates an adaptive, as well as an innate, immune response through the dendritic cell, and a variable targeting domain that can be engineered to target numerous tumor types and pathogens. Our first indication is in Ovarian cancer (the fifth greatest cancer killer in women). The platform has demonstrated the ability to inhibit tumor growth in syngeneic tumor models expressing target gene. Additionally, the platform has shown activation of t-cell memory. Using the platform, we have recently developed a highly effective COVID-19 Vaccine, which, stimulates a robust antibody response, T-cell activation, and does not require an adjuvant, and promises increased durability compared to existing vaccines. Additionally, by activating an antigen specific Treg response, we have begun to develop and autoimmune disease program. OmniCyte boasts a strong management team and an even stronger bench of advisors & collaborators including key opinion leaders in oncology, immunology and biotech business. The platform is protected by broad issued patents, US and foreign. We have just completed raising a seed investment round to fund pre-IND work for Omn007, and are preparing to raise a $15M Series A round to fund first in human trials. Vaccine development is funded through partner and grant funding.

OmniCyte Home